ARTICLE ADMEDUS LTD OPENS RIGHTS ISSUE TO SUPPORT STRONG GROWTH
August 18 2016
Healthcare company, Admedus, will use the funds raised from the placement and the rights issue for its corporate restructure, with the majority allocated for working capital.
ARTICLE ADMEDUS LTD POCKETS A$10M FROM OVERSUBSCRIBED PLACEMENT
July 29 2016
Wayne Paterson, chairman and interim CEO, commented: “This capital raise will allow us to continue our current strong sales growth and roll-out additional products into the cardiovascular markets, whilst implementing our corporate strategy of tighter expenditure control."
NEWSWIRE ADMEDUS LTD TO OUTLINE CAPITAL RAISING
July 27 2016
ARTICLE ADMEDUS LTD WINS THE PEER VOTED ‘MANUFACTURER OF THE YEAR’ AWARD
May 13 2016
Admedus was also awarded ‘Most Innovative Manufacturing Company’ for its work in the research, manufacture and export of its lead regenerative tissue product CardioCel®.
ARTICLE ADMEDUS LTD TO SHOWCASE CARDIOCEL® IN THE U.S. TO DRIVE SALES
May 12 2016
Lee Rodne, managing director, commented: "We believe CardioCel represents a disruptive technology and we are concentrating on building awareness of our product in this market."
ARTICLE ADMEDUS LTD POSTS 73% INCREASE IN MARCH QUARTER SALES
April 29 2016
Admedus recorded a strong March quarter with sales of $3.3 million, up 73% on the corresponding period last year. The company now anticipate recording its strongest ever revenue performance for the June quarter 2016.
ARTICLE ADMEDUS LTD EXPANDS DISTRIBUTION AGREEMENT WITH CORONEO
April 08 2016
Admedus has extended its distribution agreement with Coroneo to sell its products, including is Aortic Annuloplasty Ring, in Australia and New Zealand. The Coroneo Aortic Annuloplasty Ring is a complementary product to CardioCel for repairs of aortic heart valves.
ARTICLE ADMEDUS LTD DEMONSTRATES CLOSE PROFILE TO NATIVE AORTIC VALVE
March 29 2016
New York based Maxim Group has a $2.00 12-month target price on Admedus, which is around four-times higher than the last trading price. This follows CardioCel demonstrating a close profile to native aortic valve.
ARTICLE ADMEDUS LTD RECEIVES $2.00 PRICE TARGET FROM NEW YORK BASED MAXIM GROUP
March 14 2016
Maxim Group said: "Our model only includes CardioCel in CHD and heart valve repair for conservatism. We use free-cash-flow-to-the-firm (FCFF), discounted-EPS, and sum-of-the-parts models, with a risk rate of 30%, equally weighted and averaged, to derive our $2.00 price target."
ARTICLE ADMEDUS LTD RECEIVES A$1.95 VALUATION FROM HONG KONG FIRM
March 10 2016
Cedrus Investments commented: "We are initiating coverage of Admedus. In our view, shares of Admedus are currently undervalued, as we estimate they will have a fair value of A$1.95 per share by December 2018, versus the closing price of A$0.42 as of March 8, 2016."
NEWSWIRE ADMEDUS LTD CHAIRMAN ACQUIRES SHARES ON MARKET
March 09 2016
ARTICLE ADMEDUS TO ADD REVENUE AS HEART DISEASE TECH DISTRIBUTION GROWS
January 27 2016
Admedus has made a cost-effective improvement to its sales capacity and revenue potential by signing a European distribution deal for a range of heart reconstruction technologies that will be managed by existing in-house resources.
AHZ Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
(20min delay)